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Abstract
Background: While infections with human papillomavirus (HPV) are highly prevalent among sexually active young 
women in Uganda, information on incidence, clearance and their associated risk factors is sparse. To estimate the 
incidence, prevalence and determinants of HPV infections, we conducted a prospective follow-up study among 1,275 
women aged 12-24 years at the time of recruitment. Women answered a questionnaire and underwent a pelvic 
examination at each visit to collect exfoliated cervical cells. The presence of 42 HPV types was evaluated in exfoliated 
cervical cells by a polymerase chain based (PCR) assay (SPF10-DEIA LiPA).
Results: Three hundred and eighty (380) of 1,275 (29.8%) women were followed up for a median time of 18.5 months 
(inter-quartile range 9.7-26.6). Sixty-nine (69) women had incident HPV infections during 226 person-years of follow-up 
reflecting an incidence rate of 30.5 per 100 person-years. Incident HPV infections were marginally associated with HIV 
positivity (RR = 2.8, 95% CI: 0.9 - 8.3). Clearance for HPV type-specific infections was frequent ranging between 42.3% 
and 100.0% for high- and 50% and 100% for low-risk types. Only 31.2% of women cleared all their infections. Clearance 
was associated with HIV negativity (Adjusted clearance = 0.2, 95% CI: 0.1 - 0.7) but not with age at study entry, lifetime 
number of sexual partners and multiplicity of infections. The prevalence of low-grade squamous intraepithelial lesions 
(LSILs) was 53/365 (14.5%). None of the women had a high-grade cervical lesion (HSIL) or cancer. Twenty-two (22) of 
150 (14.7%) HPV negative women at baseline developed incident LSIL during follow-up. The risk for LSIL appeared to 
be elevated among women with HPV 18-related types compared to women not infected with those types (RR = 3.5, 
95% CI: 1.0 - 11.8).
Conclusions: Incident HPV infections and type-specific HPV clearance were frequent among our study population of 
young women. These results underscore the need to vaccinate pre-adolescent girls before initiation of sexual activity.
Background
Persistent infection with one or more high-risk HPV
types is an important etiologic factor in the development
of cervical cancer [1]. High-risk HPV types are extremely
prevalent among young sexually active women in Uganda
infecting about half of those aged 12-24 years [2]. Most
infections in young women with or without cervical
abnormalities are described as being transient [3-5] as
approximately 90% of women cleared a specific type of
HPV within 24 months [6]. Vaccination against high-risk
types of HPV may be the most realistic intervention to
reduce substantially the cervical cancer burden particu-
larly in populations where Pap screening has largely been
absent or ineffective [7]. Cohort studies pose challenges
for researchers in Africa; particularly, retaining study
subjects after recruitment. Consequently, information on
type-specific HPV infections, clearance and potential risk
factors is sparse. In Uganda, the only information avail-
able derives from two separate studies conducted among
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young primiparous [8] and young and adult women in a
rural district [9]. Yet, this information is important to fur-
ther the understanding of the natural history of HPV
infections among Ugandan women as we prepare for the
introduction of a vaccine against HPV infections. In this
article we report findings on incidence, clearance and risk
factors for HPV infections in a cohort of Ugandan women
aged 12-24 years.
Methods
Study population and follow-up visits
Women were recruited and followed up between Sep-
tember 2002 and December 2006. A description of the
study population at baseline is available elsewhere [2].
Briefly, participants were recruited among women aged
12-24 years presenting themselves for health services at
Naguru Teenage Information and Health Centre
(NTIHC) located in the suburbs of Kampala City.
Women were eligible for participation if they were sexu-
ally active, resided within 20-kilometer radius of NTIHC
and had no plans to relocate for the duration of the study.
Follow-up visits were scheduled between 6-12, 13-18, and
19-24 months from baseline. Twenty-nine women who
turned up for visits after 24 months were not turned
away, although these visits were unscheduled.
Gynaecological examination, collection of exfoliated cells 
and cytological assessment
During all visits, trained midwives explained the study
aims and procedures, which included answering a ques-
tionnaire and having a pelvic examination to record visi-
ble abnormalities. In all visits after visual inspection of
the vulva, a non-lubricated sterile speculum was inserted,
and cervical exfoliated cells were collected. At the first
visit at cohort enrolment, cervical exfoliated cells were
collected with a sterile swab (Copan International) which
was then placed in a labelled 15 mL holding tubes con-
taining 5 mL of phosphate buffered saline (PBS), pH 7.2;
samples were kept temporarily at 4°C for an average of 6
hours and then transferred to a freezer for storage at 20°C
until shipment to the laboratory for HPV analysis. PBS is
not a suitable solution for preservation of cells for liquid
based cytology and consequently no liquid based cytol-
ogy could be done with baseline samples. However, dur-
ing follow-up, cervical exfoliated cells were collected and
stored in a vial containing PreservCyt solution (Cytyc,
Boxborough, MA) which is suitable both for liquid-based
cytology and HPV testing. Briefly, for these follow-up
samples, a broom style cytobrush (Cervex brush, Rovers
Medical Devices B.V., Oss. The Netherlands) was inserted
deep into the endocervical canal and rotated gently in a
clockwise direction 5 times to collect cells from the endo-
and ectocervix. The cytobrush containing cervical cellu-
lar material was then placed in a vial containing Preserv-
Cyt solution (Cytyc) and rinsed by pushing it to the
bottom of the vial 10 times. The cytobrush was then dis-
carded. The vials were closed and kept at room tempera-
ture until shipment in dry ice to DDL Diagnostic
Laboratory, Voorburg, The Netherlands, for liquid based
cytology and HPV testing. Cervical abnormalities in liq-
uid-based cytology samples were read at the cytology
department of the Slotervaart Hospital, Amsterdam, The
Netherlands and classified according to the 2001
Bethesda Classification [10].
Before removal of the speculum, both for the baseline
and follow up visits, visual inspection with acetic acid
(VIA) and with Lugol's Iodine (VILI) was performed. A
urine sample and 4 ml of blood (in heparinised tubes)
were collected for pregnancy, HIV and syphilis testing,
respectively. Non-pregnant women with external genital
warts were treated with 2% podophylline paint. The treat-
ment of pregnant women was deferred until after deliv-
ery. Women with vaginal discharge and cervicitis
received a one-week syndromic treatment and were
requested to ask their sexual partners to receive treat-
ment.
Isolation of HPV DNA
Total DNA was isolated from 200 μl of the suspension
containing the cervical cells by the MagNa Pure LC
instrument (Roche Diagnostics, Almere, The Nether-
lands), using the Total NA isolation kit (Roche Diagnos-
tics, Almere, The Netherlands). DNA was eluted in 100 μl
of elution buffer, and 10 μl was used for each PCR reac-
tion. Each run contained positive and negative controls to
monitor the DNA isolation, PCR and HPV detection and
genotyping procedures.
PCR testing
The short PCR fragment (SPF) 10 primer set was used to
amplify a broad spectrum of HPV genotypes, as
described earlier [11,12]. Briefly, this primer set amplifies
a small fragment of 65 base pairs (bps) from the L1 region
of HPV. Reverse primers contain a biotin label at the 5'
end, which enables capture of the reverse strand onto
streptavidin coated microtiter plates. Captured amplim-
ers are denatured by alkaline treatment and a defined
cocktail of digoxigenin - labeled probes, detecting a broad
spectrum of HPV genotypes. This method is designated
HPV DNA enzyme immunoassay (DEIA), and provides
an optical density value. The same (SPF) 10 amplimers
were used to identify the HPV genotype by reverse
hybridisation on a line probe assay (LiPA) containing
probes for 25 different genotypes [(SPF) 10 HPV LiPA
version 1, Labo Bio-medical Products, Rijswijk, the Neth-
erlands]. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
and 68/73 were considered high-risk types and 6, 11, 34,
40, 42, 43, 44, 53, 54, 66, 70 and 74 were considered low-Banura et al. Infectious Agents and Cancer 2010, 5:7
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risk types [13]. Samples that were positive using the (SPF)
10 primer set but did not reveal any of the 25 aforemen-
tioned types, were provisionally classified as positive for
HPV X and were subjected to a second round of testing,
similar to the one already described, for 17 additional
types including HPV 26, 30, 55, 61, 62, 64, 67, 69, 71, 82,
83, 84, 85, 87, 89, 90 and 91.
HIV Testing
HIV-1 testing was performed at NTIHC following the
National HIV Rapid Testing algorithm consisting of
Determine rapid test (Abbot Diagnostics, Abbot Park, IL)
as screening test, Statpak rapid test (ChemoBio Diagnos-
tics, Systems, Inc. Medford, NY) as the confirmatory test
and Unigold (Orgenics, Waltham, MA) as tie breaker
[14]. For quality assurance and quality control, all HIV-
positive results were confirmed by ELISA (Cambridge
Bioscience, Cambridge, UK) or PCR assays (Roche
Molecular Systems, Pleasanton, CA) at Makerere Medical
School. Women found to be HIV-positive were referred
to health institutions offering treatment, care and sup-
port services.
Syphilis testing
Syphilis testing was performed at NTIHC using a com-
mercially available standard Rapid Plasma Reagin (RPR)
18 mm circle card test (Quorum Diagnostics, Sacra-
mento, CA). Samples with reactive RPR test results were
referred to established laboratories for confirmation
before treatment was offered to the women concerned
and their partners.
Pregnancy testing
All women were tested for pregnancy using a commer-
cially available HCG dipstick pregnancy test (Cypress
Diagnostics, Langdorpsesteenweg, Belgium), and the
results were communicated immediately to each woman.
By the end of the study 30 women were tested positive for
pregnancy. The pregnant women were referred for free
pre-natal counselling, evaluation and care within the
same health care center. Only the pre-natal care services
are being evaluated in our study, not the number of weeks
of pregnancy or the decision if the pregnancy was or not
to be kept.
Ethical considerations
Women consented to participation in the study. The
women younger than 18 years of age were treated accord-
ing to the Uganda guidelines for conducting research on
human beings that allows minors to assent for participa-
tion without a parent or legal guardian agreement. These
guidelines are approved by the ethical review committees
at the Faculty of Medicine, Makerere University, the
Uganda National Council of Science and Technology, and
the International Agency for Research on Cancer.
Statistical analyses and definitions of outcomes
We analyzed incidence and clearance of HPV infection
for all women who had at least one follow-up visit. Any
HPV type was defined as a combined outcome if any
HPV type was present. We defined HPV 16-related types
as HPV 16, 31, 33, 35, 52, and 58 and HPV 18-related
types as HPV 18, 39, 45, 59 and 68. Single and multiple
infections were defined without considering uncharacter-
ized HPV types (HPV X). We computed relative risk (RR)
for HPV incidence and clearance using Poisson regres-
sion dividing the follow-up time in 6-month windows for
risk time and events.
For incidence analysis, the risk time was measured for
each specific HPV type or combined set of HPV types
from the first time a woman tested negative until a posi-
tive test or the last visit.
For each of the groups of infections (low-risk, high-risk,
HPV 16-related, HPV 18-related and any HPV) incidence
was calculated for women free from all the infections in
each group until infection of at least one of the HPV types
in the group. Correspondingly clearance was calculated
for all women infected with at least one of the HPV types
in each group until the woman was free from infection of
all the HPV types in each group. Thus, clearance will typ-
ically be a lot longer than for specific HPV types. This
c h o i c e  o f  g r o u p s  o f  H P V  t y p e s  i n t e n d  t o  m e a s u r e  a n
exposure assuming interchangeable risks within the
group so a woman was not considered cleared from expo-
sure of high-risk HPV if one high-risk infection was
cleared while she was still infected with other high-risk
type(s). Thus, clearance of any HPV was interpreted as
being cleared from all HPV infections. Highly sexually
active women as our study population would tend to have
long clearance time even if each specific type is cleared
fast.
Women positive for HPV X at baseline who tested pos-
itive for a known HPV type at follow-up visit were con-
sidered to have developed a new infection in the analysis
of incidence but were excluded from the analysis of clear-
ance as persistence of HPV X could not be known. For
each HPV type, we fitted Poisson models including a time
covariate only and models adjusting for HIV status, age at
baseline (12-17, 18-20, 21-24 year), positivity for genital
warts or syphilis (yes/no), and lifetime number of sexual
partners (1, 2, 3, ≥4).
We evaluated prevalent cytological abnormalities only
on follow-up visits as the medium used to collect baseline
specimens was not suitable for cytological analysis. Sub-
jects were classified as normal or low-grade squamous
intraepithelial lesions (LSILs). No high-grade squamous
intraepithelial lesions or invasive cervical cancer cases
were diagnosed. Among women with a baseline HPV
negative sample with valid follow-up cytological sample
we evaluated incident cytological abnormalities accord-Banura et al. Infectious Agents and Cancer 2010, 5:7
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ing to type-specific HPV infections at follow-up (HPV 16
infected vs. non-infected, HPV 18 infected vs. non-
infected, high-risk infected vs. non-infected, low-risk
infected vs. non-infected, HPV 16-related types infected
vs. non-infected, HPV 18-related vs. non-infected and
infection with any HPV type vs. non-infected).
All tests of statistical hypotheses were made on the
two-sided 5% level of significance with corresponding
95% confidence intervals. All analyses were made using
the SAS software version 9.2 (SAS Corp). Procedure gen-
mod was used to fit the Poisson regression.
Results
Characteristics of the cohort
Of the 1,275 women enrolled in the study at baseline,
only 380 (29.8%) women had at least one follow-up visit.
Compared to women with adequate follow-up, the
women with inadequate follow-up were slightly younger
at study entry (>18 years 85.5% vs. 90.3%), less likely to
have genital warts (7.6% vs. 8.2%), less likely to be preg-
nant at time of examination (11.8% vs. 15.0%) but more
likely to be HIV positive (6.2 vs. 5.8%) and more likely to
have initiated sex below 15 years (15.0% vs.10%). There
was no difference at baseline between women who were
adequately followed up and those who were not with
respect to HPV positivity (74.6% vs. 74.7%) and the num-
ber of lifetime sexual partners (≥2 or more; 74.8% vs.
74.4%). The time between visits was highly variable. The
median time to the 1st follow-up visit was 18.5 months,
with inter - quartile range of 9.7 to 26.6 months (Figure
1).
Table 1 shows HPV incidence and clearance between
March 2003 and December 2006. The overall prevalence
with any HPV type at baseline was 75.3% with cumulative
positivity of 86.6%. Except for HPV 34, all the common
high- and low-risk types were detected. The 5 most com-
mon high-risk types cumulatively detected in descending
order were HPV 51 (n = 76, 20.0%), HPV 52 (n = 71,
18.7%), HPV 16 (n = 58, 15.3%), HPV 18 (n = 56, 14.7%)
and HPV 33 (n = 52, 13.7%). Of the most common low-
risk types, HPV 6 (n = 94, 24.7%), HPV 11 (n = 62, 16.3%)
and HPV 66 (n = 35, 9.2%) were frequently detected.
Cumulatively, high-risk HPV types (68.2%) were more
frequently detected than low-risk types (55.0%). Single
infections (55.3%) were slightly more common than mul-
tiple infections (47.6%) as were HPV 16-related types
(48.6%) compared to HPV 18-related types (28.2%).
Cumulatively, 75 (19.7%) infections were uncharacterized
(HPV X) after the first round of testing and went through
a second round of testing for an additional 17 types.
Thirty-three (33) women could be assigned one or more
specific types after the second round of testing leaving 42
(11.1%) women as HPV X. Further work on HPV X is cur-
rently ongoing which is detecting other types not identi-
fied in the established SPF-10.
Incidence of HPV infections
Table 2 shows the type-specific HPV incidence rates of
155 HPV negative women at baseline followed up
between March 2003 and December 2006. Sixty-nine
women had an incident HPV infection during 226 per-
son-years of observation, reflecting an incidence rate of
30.5 per 100 person-years. Type-specific incidence rates
ranged between 0.8 and 4.2 per 100 person-years of
observation for high-risk HPV types and between 1.1 and
3.4 per 100 person-years for common low-risk types.
Incident high-risk types (20.9 per 100 person-years) were
more frequent than low-risk HPV types (10.6 per 100
person-years). Incident infections with HPV 16-related
were twice as likely as HPV 18-related types (10.8 and 5.6
per 100 person-years, respectively). Incident HPV infec-
tions were marginally associated with HIV positivity (RR
= 2.8, 95% CI: 0.9 - 8.3) but not with age at study entry,
and lifetime numbers of sexual partners (Table 3).
Clearance of HPV infections
Overall, 143 women with prevalent infections cleared
their infections during 459 person-years of observation
reflecting complete clearance for all HPV types of 31.2%
(Table 2). Clearance for specific types ranged between
42.3% and 100.0% for high-risk and 50% and 100.0% for
low-risk HPV types. Women with high-risk types (42.2%)
cleared their HPV infections as much as those with low-
risk types (47.3%). However, women with HPV 16-related
types (51.0%) cleared their infections less than those with
HPV 18-related types (65.5%). Clearance was only associ-
ated with HIV seronegativity (RR = 0.3, 95% CI: 0.1 - 0.8)
but not with age at study entry, lifetime number of sexual
partners, and multiplicity of infections.
I n ci d e n t  HPV  i n f ect i o n s  w e r e  c o m m o n  i n  bo t h  H IV
positive (rates between 2.2 and 15.4 per 100 person-
years) and HIV negative women (rates between 0.8 and
4.2 per 100 person-years) [See Additional file 1: Table S1
f o r  o r i g i n a l  d a t a  u s e d  t o  p e r f o r m  t h i s  a n a l y s i s ] .  C o m -
pared to HIV negative women, the risk for incident infec-
tions was elevated for low-risk HPV types (RR = 3.3, 95%
CI: 1.4 - 7.8) and HPV 16-related types (RR = 3.0, 95% CI:
1.3 - 6.9) in HIV positive women and the difference was
statistically significant. The risk for any HPV type (RR =
2.8, 95% CI: 0.9 - 8.3) and for high-risk types (RR = 2.1,
95% CI: 0.9 - 5.1) was of borderline statistical significance
among HIV positive compared to HIV negative women.
There was no difference in risk for HPV 18-related types
(RR = 1.8, 95% CI: 0.5 - 6.2); single infections (RR = 1.1,
95% CI: 0.5 - 2.3), multiple infections (RR = 2.2, 95% CI:
0.6 - 7.6) and HPV - other X (RR = 0.9, 95% CI: 0.5 - 1.8)
among HIV positive compared to HIV negative women.Banura et al. Infectious Agents and Cancer 2010, 5:7
http://www.infectagentscancer.com/content/5/1/7
Page 5 of 12
Clearance was significantly less for any HPV and multiple
infections among HIV positive women compared to HIV
negative women (Adjusted clearance = 0.2, 95% CI: 0.1 -
0.7) and the difference was statistically significant. There
was no statistically significant difference in clearance of
any high- or low-risk HPV types, HPV 16-related, HPV
18-related and single infections between HIV positive
and negative women.
Prevalence and Incidence of LSIL
Three hundred seventy-eight (378) of 380 (99.5%) women
with at least one follow-up visit provided a sample for liq-
uid-based cytology. Twelve (12) samples were inadequate
leaving 365 samples for cytological analysis; of these 365
samples, 53 (14.5%) had LSILs. None of the women had
HSIL or cancer. One hundred and seventy-three (173)
women provided at least 2 samples for cytologic analysis
of which, 5 and 3 samples were inadequate at 1st and 2nd
follow-up visit leaving 168 and 170 samples, respectively,
available for cytological analysis. The prevalence of LSILs
at 1st cytologic sample was 15/168 (8.9%) and declined to
9/170 (5.3%) at the 2nd visit. Evaluation incident LSIL was
possible for 150/155 (96.8%) women who were HPV DNA
negative at baseline. Twenty-two (22) of 150 (14.7%)
developed LSILs between baseline and 1st  follow-up
(Table 4). Incident LSILs appear to be more frequent
among women infected with HPV 18-related types com-
pared to women not infected with those types (RR = 3.5,
95% CI: 1.0 - 11.8), though the difference is of borderline
statistical significance.
Figure 1 Follow-up visits according to time (in months) since last visit.
M
o
n
t
h
 
s
i
n
c
e
 
l
a
s
t
 
v
i
s
i
t
0
6
12
18
24
30
36
42
48
Visit
23456Banura et al. Infectious Agents and Cancer 2010, 5:7
http://www.infectagentscancer.com/content/5/1/7
Page 6 of 12
Table 1: Cumulative positivity of HPV infections among 380 women up to 3 follow-up visits between March 2003 and 
December 2006 in Kampala, Uganda
Prevalence at entry (%) Cumulative positivity (%) Positive once (%) Positive ≥ 2 visits (%)
Infections with high-risk HPV types
16 42 (11.1) 58 (15.3) 49 (12.9) 9 (2.4)
18 47 (12.4) 56 (14.7) 50 (13.2) 6 (1.6)
31 24 (6.3) 43 (11.3) 36 (9.5) 7 (1.8)
33 41 (10.8) 52 (13.7) 46 (12.1) 6 (1.6)
35 22 (5.8) 40 (10.5) 33 (8.7) 7 (1.8)
39 18 (4.7) 26 (6.8) 21 (5.5) 5 (1.3)
45 11 (2.9) 20 (5.3) 16 (4.2) 4 (1.1)
51 54 (14.2) 76 (20.0) 59 (15.5) 17 (4.5)
52 49 (12.9) 71 (18.7) 52 (14.2) 17 (4.5)
56 32 (8.4) 54 (14.2) 47 12.4) 7 (1.8)
58 8 (2.1) 22 (5.8) 19 (5.0) 3 (0.8)
59 8 (2.1) 15 (3.9) 12 (3.2) 3 (0.8)
68-73 20 (5.3) 35 (9.2) 30 (7.9) 5 (1.3)
39-68-73 8 (2.1) 11 (2.9) 11 (2.9) 0 (0.0)
Infections with low-risk HPV types
6 74 (19.5) 94 (24.7) 82 (21.6) 12 (3.2)
11 55 (14.5) 62 (16.3) 59 (15.5) 3 (0.8)
34 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
40 17 (4.5) 20 (5.3) 17 (4.5) 3 (0.8)
42 2 (0.5) 2 (0.5) 2 (0.5) 0 (0.0)
43 19 (5.0) 22 (5.8) 19 (5.0) 3 (0.8)
44 6 (1.6) 14 (3.7) 8 (2.1) 6 (1.6)
53 12 (3.2) 17 (4.5) 15 (3.9) 2 (0.5)
54 9 (2.4) 21 (5.5) 15 (3.9) 6 (1.6)
66 20 (5.3) 35 (9.2) 27 (7.1) 8 (2.1)
70 11 (2.9) 18 (4.7) 13 (3.4) 5 (1.3)
74 2 (0.5) 7 (1.8) 4 (1.1) 3 (0.8)
HPV Xa 26 (6.8) 75 (19.7) 66 (17.4) 9 (2.4)
HPV other X b 8 (2.1) 42 (11.1) 38 (10.0) 4 (1.1)
Number of women with:
- Any HPV types 286 (75.3) 329 (86.6) 122 (32.1) 207 (54.5)
- High-risk HPV types 197 (51.8) 259 (68.2) 139 (36.6) 120 (31.6)
- Low-risk HPV types 167 (43.9) 209 (55.0) 144 (37.9) 65 (17.1)
- Single infections 102 (26.8) 210 (55.3) 142 (37.4) 68 (17.9)
- Multiple infections 152 (40.0) 181 (47.6) 124 (32.6) 57 (15.0)
-HPV 16--related c 127 (33.4) 178 (46.8) 113 (29.7) 65 (17.1)
-HPV 18--related d 77 (20.3) 107 (28.6) 82 (21.6) 25 (6.6)
a HPV X includes types 26, 30, 55, 61, 62, 64, 67, 69, 71, 82, 83, 84, 87, 89, 90 and other unknown types
bHPV-other X, i.e. type unknown
c Includes HPV 16, 31, 33, 35, 52 and 58;
d Includes HPV 18, 39, 45, 59, 68Banura et al. Infectious Agents and Cancer 2010, 5:7
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Table 2: HPV incidence and clearance between March 2003 and December 2006, Kampala, Uganda
Incidence Clearance
HPV type Incident
casesa
Person
years
Incidence 
rate
per 100 p. yrs
Number
cleared
Person
years
Clearance
rate
per 100 p. yrs
High-risk 
types
16 16 487 3.3 45 63 71.4
18 10 491 2.0 47 59 79.7
31 20 727 2.8 25 29 86.2
33 13 407 3.2 43 43 100.0
35 19 527 3.6 22 52 42.3
39 8 540 1.5 17 29 58.6
45 9 696 1.3 11 20 55.0
51 25 602 4.2 54 90 60.0
52 23 674 3.4 45 84 53.6
56 24 697 3.4 40 50 80.0
58 14 558 2.5 10 11 90.9
59 8 508 1.6 10 19 52.6
68 10 749 1.3 5 1 100.0
68-73 15 529 2.8 25 39 64.1
39-68-73 3 399 0.8 9 11 81.8
Low-risk types
6 22 651 3.4 69 107 64.5
11 8 440 1.9 59 116 50.9
34 0 0 0.0 0 0 0.0
40 4 288 1.1 18 26 46.2
42 0 0 0.0 2 1 100.0
43 3 225 1.3 18 23 78.3
44 8 713 1.1 5 6 83.3
53 5 289 1.7 13 18 72.2
54 14 735 1.9 14 15 93.3
66 15 649 2.4 19 38 50.0
70 7 600 1.2 11 9 100.0
74 5 373 1.3 2 1 100.0
HPV Xb other 
types
50 701 7.1 39 55 70.9
HPV X c 33 550 6.0 15 18 83.3
Number of 
women with:Banura et al. Infectious Agents and Cancer 2010, 5:7
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HIV testing at follow-up
The majority of women who were tested HIV positive
during follow-up had declined HIV testing at enrolment;
We suppose that the women already knew they were HIV
positive therefore we chosen to not provide the analysis
of HIV incidence during follow-up.
Discussion
The observed high incidence rate of HPV infections
among the young women in our study is similar to finding
described in previous studies [15-17]. A woman's risk for
incident infection was defined by her HIV serostatus.
Indeed, women infected with HIV were twice as likely as
HIV negative women to have incident infection with
high- or low-risk HPV types in agreement with published
studies [18]. The difference in risk for incident HPV 16
and HPV18 infections was not statistically significant in
both HIV positive and negative women. Safaeian et al.
(2008) [9] in a population-based study in a rural district
of Uganda, found a 3-fold elevated risk for HPV 16 and
HPV 18 among HIV positive compared to HIV negative
women. In their study, the study population consisted of
both young and old women aged 15 - 55 years and this
could explain the difference between our findings and
theirs. However, the limited sample size in our study
could have limited our ability to detect a difference.
Despite the limited age range of the women in our study,
we found higher incidence rate for high- than for low-risk
HPV types, similar to studies with a wide age ranges [19-
21].
Our findings differ from studies conducted among
adult populations who found that the 12-month clearance
for low-risk HPV types was more than for high-risk types
but no clear difference between infections with high-risk
types other than HPV 16 [19]. The different sensitivity of
HPV DNA detection assays used in other studies com-
pared to ours and the age structure of the population of
women studied might explain the observed differences.
Nevertheless, HPV 16 tend to persist longer than other
HPV types as observed in several follow-up studies of
adult populations unlike our study population that com-
prised of young women whose HPV infections were more
likely to be transient [22-24]. Clearance was associated
with HIV seronegativity but not with age at study entry,
lifetime number of sexual partners, and multiplicity of
infections at the beginning of follow-up. The women's
characteristics associated with clearance of infections
with HPV are not consistent across studies [9,19,25,26].
For instance, some studies have reported less clearance of
HPV infection in women with more lifetime sexual part-
ners, a finding suggestive of past exposure or reactivated
infections acquired earlier, which may not be prone to
clearance. In our study, however, HPV infections were
not associated with number of lifetime sexual partners
perhaps because prior exposure to HPV infection may
have been limited given the young age of our study popu-
lation. Only 31.2% of women had cleared all their infec-
tions by the end of the follow-up period. Considering the
median time to first follow-up in our study was 18.5
months, this period was probably long enough for a
woman to clear an infection and get re-infected with the a
different or even the same HPV type. Thus, it is possible
that our observed clearance was likely to be of incident
infections acquired subsequently rather than the initial
prevalent infections that the woman had at baseline.
- Any HPV 69 226 30.5 143 459 31.2
- High-risk 85 407 20.9 145 344 42.2
- Low-risk 49 461 10.6 138 292 47.3
- Single 
infections
115 532 21.6 104 218 47.7
- Multiple 
infections
42 508 8.3 133 241 55.2
- HPV 16-
related d
59 547 10.8 106 208 51.0
- HPV 18-
related e
36 640 5.6 76 116 65.5
Note; The figures do not add up because of missing figures
Abbreviations: P. yrs, person-years; HR, high-risk; LR, low-risk
a Crude numbers
b HPV types detected at a 2nd round of testing: HPV 26, 30, 55, 61, 62, 64, 67, 69, 71, 82, 83, 84, 87, 89, 90, and other unknown types
cHPV X, i.e. type unknown
d Includes HPV 16, 31, 33, 35, 52 and 58
e Includes HPV 18, 39, 45, 59, 68
Table 2: HPV incidence and clearance between March 2003 and December 2006, Kampala, Uganda (Continued)Banura et al. Infectious Agents and Cancer 2010, 5:7
http://www.infectagentscancer.com/content/5/1/7
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Table 3: HPV incident and clearance cases and rates per 100 person-years and RR according to different women's 
characteristics
Baseline
Characteristics
Incidence Clearance
Distribution
women (%)
Person
years
Rate
per 100 p. 
yrs
RR (95% 
CI)a
Distribution
women (%)
Person
years
Rate
per 100 p. 
yrs
RR (95%
CI)a
Age (yrs) at study entry
21 -- 24 78 (50.3) 115 25.3 1 (ref.) 145 (47.4) 72 9.8 1 (ref.)
18 -- 20 62 (40.0) 92 32.6 1.2 (0.7 -- 2.0) 128 (41.8) 64 7.8 0.7 (0.5-1.0)
12 -- 17 15 (9.7) 19 53.3 2.2 (1.0 -- 4.5) 33 (10.8) 16 0 0.9 (0.5-1.5)
Lifetime number of sexual partners
1 47 (30.3) 66 30.1 1 (ref.) 73 (23.9) 36 8.3 1 (ref.)
2 45 (29.0) 78 26.8 0.8 (0.4 -- 1.5) 91 (29.7) 45 11.1 0.9 (0.6-1.5)
3 36 (23.2) 46 36.8 1.5 (0.8 -- 2.9) 73 (23.9) 36 2.7 0.9 (0.5-1.4)
4 or more 27 (17.4) 34 32 1.1 (0.5 -- 2.3) 69 (22.5) 34 8.7 1.0 (0.6-1.6)
HIV status
Negative 148 (95.5) 212 29.7 1 (ref.) 272 (88.9) 135 8.9 1 (ref.)
Positive 4 (2.6) 6 65 2.8 (0.9 -- 8.3) 20 (6.5) 10 0 0.3 (0.1-0.8)
Unknown 3 (1.9) 7 27.2 - 14 (4.6) 7 0 -
Multiplicity of HPV types b
No infection -- -- -- -- 28 (9.2) 14 14.5 1 (ref.)
Single -- -- -- -- 108 (35.3) 54 5.6 0.5 (0.3-1.0)
2 or more types -- -- -- -- 170 (55.6) 841 8.3 0.6 (0.4-1.2)
Note 1: The figures do not add up because of missing values
Note 2: The denominator is person-years
Abbreviations: CI, Confidence Intervals; p. yrs, person-years
a adjusted for age, number of sexual partners and HIV infection
b 2 or more types compared to 1 infection: for clearance 1.3 (0.9-1.8)
Despite the high incidence of HPV infections, the inci-
dence of LSIL was relatively low (14.5%) which suggests
that many young women who were infected with HPV
had no cellular changes. Moscicki et al. (2001) [27], in a
study of 496 adolescents and young women found that
only 25% of those who acquired HPV infections devel-
oped LSILs. It is believed that LSIL is merely a manifesta-
tion of HPV infection [27] and indeed LSIL seemed to be
more frequent among women infected with HPV 18-
related types than those not infected with those types.
The decline in prevalent LSIL from 8.9% to 5.3% between
the 1st and 2nd visit in women who provided at least 2 ade-
quate samples for cytologic analysis underscores the tran-
sient nature of HPV infection and associated cervical
lesions among young women. Our findings therefore,
imply that initiating screening for cervical cancer in
young women is likely to detect transient low-grade cer-
vical abnormalities. Current knowledge of the natural
history of HPV infection and its associated cervical
lesions suggest that conservative management, such asBanura et al. Infectious Agents and Cancer 2010, 5:7
http://www.infectagentscancer.com/content/5/1/7
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Table 4: LSIL incidence among women with normal cytology followed upbetween March 2003 and December 2006 in 
Kampala, Uganda
HPV type No. of
women
Person
years
Incident
LSIL
Incidence
rate per
100 p. yrs
Crude RR
(95% CI)a
Infected/non-
infected
p-value
HPV 16
Non-infected 142 114 21 18.4 1
Infected 8 9 1 11.1 0.5 (0.1 -- 3.9) 0.52
HPV 18
Non-infected 147 120 21 17.5 1
Infected 3 3 1 33.3 2.2 (0.3 -- 16.2) 0.45
High-risk HPV 
types
Non-infected 104 81 12 14.8 1
Infected 46 43 10 23.3 1.4 (0.6 -- 3.4) 0.39
Low-risk HPV 
types
Non-infected 122 99 20 20.2 1
Infected 28 24 2 8.3 0.4 (0.1 -- 1.8) 0.25
HPV 16-related b
Non-infected 124 98 18 18.4 1
Infected 26 25 4 16 0.8 (0.3 -- 2.3) 0.64
HPV 18-related c
Non-infected 142 117 19 16.2 1
Infected 8 64 3 50 3.5 (1.0 -- 11.8) 0.05
Any HPV type
Non-infected 76 58 10 17.2 1
Infected 74 65 12 18.5 1.0 (0.4 -- 2.5) 0.91
Abbreviations: CI, confidence intervals; p. yrs, person--years
aFurther adjusted for age, HIV, lifetime number of sexual partners did not change the results
bIncludes HPV 16, 31, 33, 35, 52 and 58
cIncludes HPV 18, 39, 45, 59 and 68Banura et al. Infectious Agents and Cancer 2010, 5:7
http://www.infectagentscancer.com/content/5/1/7
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follow-up without aggressive surgical treatment may be
indicated in young women with LSIL. Secondly, screen-
ing with HPV testing among young women is not useful
as many women are likely to be HPV positive as shown by
the cumulative HPV results.
Our study has strengths and limitations. We used a
highly sensitive HPV testing PCR assay for HPV detec-
tion to show a high rate of acquisition of new HPV infec-
tions in a population of young women in an area with
high-risk of cervical cancer. The same PCR assay was
used for HPV detection at baseline. Given the high sensi-
tivity of the PCR assay, under detection of HPV infections
was unlikely in our study. Thus, new infections were
unlikely to be infections previously missed and cleared
infections were unlikely to be due to errors in follow-up
samples.
Our study underscores the challenges of conducting
follow-up studies in low resource countries where resi-
dence has no proper street address. Hence our study had
significant loss to follow-up (70.2%) which could have
introduced selection bias. Women were lost to follow-up
because they could not be located, declined to have fur-
ther specimens collected or were back in school at the
time of scheduled visits. However, there was no differ-
ence between the women adequately followed up and
those who were not regarding lifetime number of sexual
partners, which is a strong and consistent risk factor for
acquisition of HPV infections. Secondly, loss to follow-up
was unlikely to be associated with the woman's HPV sta-
tus because the woman was blinded of her HPV status
throughout the follow-up period. We used prevalent
rather than incident infections to assess clearance and as
a result, some women could have lost an HPV infection
between visits and this could have led to the underesti-
mation of the clearance.
Conclusions
In conclusion, we investigated incidence, clearance and
potential risk factors of HPV infections among 380 young
women followed up in Kampala, Uganda. Our study
shows that incident HPV infections were frequently
underscoring the importance of vaccination of young
women before they become sexually active.
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